Abstract： Objective To investigate the expression of poly adenosine diphosphate ribose polymerase 1 (PARP1) and apoptosis inducing factor (AIF) in ovarian cancer and their relationship with clinicopathological characteristics and disease-free survival (DFS) of the patients.Methods A total of 70 cases of pathologically confirmed ovarian cancer tissue specimens and corresponding para cancerous tissue specimens in Songzi Hospital of Traditional Chinese Medicine from June 2015 to June 2017 were selected.The expression of PARP1 and AIF in tissue was detected by immunohistochemistry, and Spearman correlation analysis, Kapalan-Meier survival curve analysis, and Cox proportional risk model analysis were performed.Results The positive expression rates of PARP1 and AIF in ovarian cancer tissues were higher than those in para-cancerous tissues (P＜0.05).The clinical stage Ⅲ～Ⅳ, low differentiation and lymph node metastasis proportion of high PARP1 and AIF expression patients were higher than those of low PARP1 and AIF expression patients (P＜0.05).There was a high positive correlation between PARP1 and AIF expression in ovarian cancer tissues(r=0.791, P＜0.05).The median DFS of ovarian cancer patients with high PARP1 expression was 6.78 months, which was shorter than that of low PARP1 expression patients, 23.32 months (P＜0.05).The median DFS AIF of ovarian cancer patients with high AIF expression was 7.80 months, which was shorter than that of low AIF expression patients, 28.00 months (P＜0.05).Univariate analysis showed that clinical stage, differentiation degree, lymph node metastasis or not,PARP1, and AIF were all risk factors affecting the prognosis of ovarian cancer patients (P＜0.05).Multivariate Cox analysis showed that PARP1, AIF, clinical stage, and differentiation degree were independent risk factors affecting the prognosis of ovarian cancer patients (P＜0.05).Conclusion The positive expression rates of PARP1 and AIF in ovarian cancer tissues are significantly higher than those in para cancerous tissues, which are correlated with clinical stage,differentiation degree, lymph node metastasis or not, and DFS of ovarian cancer patients, and may be used as a clinical reference indexes to evaluate the prognosis of ovarian cancer patients.
Zhang M，Liu GY，Xue FX，et al.Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer[J].Gynecol Oncol，2016，141（1）：57-64.
[3]
Makvandi M，Pantel A，Schwartz L，et al.A PET imaging agent for evaluating PARP-1 expression in ovarian cancer[J].J Clin Invest，2018，128（5）：2116-2126.
[4]
Gunderson CC，Moore KN.Olaparib：an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer[J].Future Oncol，2015，11（5）：747-757.
京公网安备 11010502046607号